113 related articles for article (PubMed ID: 2672605)
21. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence.
Ardavanis A; Scorilas A; Loukeri A; Gerakini F; Pissakas G; Missitzis I; Apostolikas N; Yiotis I
Anticancer Res; 1998; 18(4B):2885-90. PubMed ID: 9713481
[TBL] [Abstract][Full Text] [Related]
22. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
23. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
[TBL] [Abstract][Full Text] [Related]
24. [Usefulness of the tumor markers in the diagnosis of idiopathic deep venous thrombosis associated cancer].
Enguídanos MJ; Todolí JA; Saro E; Salvador G; Villar J; Gómez-Biedma S; Micó L; Calabuig JR
An Med Interna; 2002 Nov; 19(11):561-6. PubMed ID: 12522891
[TBL] [Abstract][Full Text] [Related]
25. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
26. [Tumor markers in the diagnosis of solid tumors].
Koch OM
Internist (Berl); 1992 Aug; 33(8):W79-86. PubMed ID: 1526714
[No Abstract] [Full Text] [Related]
27. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
28. [Cystosarcoma phylloides of the breast. A retrospective analysis of 12 cases].
Mallebré B; Ebert A; Perez-Cantó A; Hopp H; Opril F; Weitzel H
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):35-40. PubMed ID: 8852784
[TBL] [Abstract][Full Text] [Related]
29. [Future prospects for the use of tumor markers].
Grunicke H
Wien Klin Wochenschr; 1989 Jul; 101(14):472-5. PubMed ID: 2672607
[TBL] [Abstract][Full Text] [Related]
30. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
Voorzanger-Rousselot N; Garnero P
Cancer Treat Rev; 2007 May; 33(3):230-83. PubMed ID: 17433551
[TBL] [Abstract][Full Text] [Related]
31. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
[TBL] [Abstract][Full Text] [Related]
32. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
33. Follow-up care of cancer survivors.
Galassi A
Lippincotts Prim Care Pract; 2000; 4(4):359-70; quiz 371-3. PubMed ID: 11261113
[No Abstract] [Full Text] [Related]
34. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
Gebauer G; Müller-Ruchholtz W
Anticancer Res; 1997; 17(4B):2939-42. PubMed ID: 9329569
[TBL] [Abstract][Full Text] [Related]
35. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
[TBL] [Abstract][Full Text] [Related]
36. [Limitation of clinical usefulness of tumor marker].
Ishii M
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1139-45. PubMed ID: 7544963
[TBL] [Abstract][Full Text] [Related]
37. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic sensitivity, diagnostic specificity and predictive value of the determination of tumour markers.
Wagener C
J Clin Chem Clin Biochem; 1984 Dec; 22(12):969-79. PubMed ID: 6527105
[TBL] [Abstract][Full Text] [Related]
39. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
40. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
